Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive
significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Overview

Total FundingEmployeesLast Funding DateStatus
$103,000,00011-502015-04-23Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2013-02-14$47,000,000VentureThird Rock Ventures
2015-04-23$56,000,000VentureForesite Capital, Redmile Group, Wellington Management, Casdin Capital, Cormorant Asset Management, Omega Funds, Pharmstandard, Nextech Invest, Inbio Ventures